Cancer Cell,
Journal Year:
2024,
Volume and Issue:
42(3), P. 378 - 395.e10
Published: Jan. 21, 2024
Brain
metastasis
(BrM)
is
a
common
malignancy,
predominantly
originating
from
lung,
melanoma,
and
breast
cancers.
The
vasculature
key
component
of
the
BrM
tumor
microenvironment
with
critical
roles
in
regulating
metastatic
seeding
progression.
However,
heterogeneity
major
vascular
components,
namely
endothelial
mural
cells,
still
poorly
understood.
We
perform
single-cell
bulk
RNA-sequencing
sorted
cell
types
detect
multiple
subtypes
enriched
specifically
compared
to
non-tumor
brain,
including
previously
unrecognized
immune
regulatory
subtypes.
integrate
human
data
mouse
models,
creating
platform
interrogate
targets
for
treatment
BrM.
find
that
CD276
checkpoint
molecule
significantly
upregulated
vasculature,
anti-CD276
blocking
antibodies
prolonged
survival
preclinical
trials.
This
study
provides
important
insights
into
complex
interactions
between
cancer
translational
relevance
designing
therapeutic
interventions.
Molecular Cancer,
Journal Year:
2023,
Volume and Issue:
22(1)
Published: Oct. 2, 2023
Abstract
Despite
centuries
since
the
discovery
and
study
of
cancer,
cancer
is
still
a
lethal
intractable
health
issue
worldwide.
Cancer-associated
fibroblasts
(CAFs)
have
gained
much
attention
as
pivotal
component
tumor
microenvironment.
The
versatility
sophisticated
mechanisms
CAFs
in
facilitating
progression
been
elucidated
extensively,
including
promoting
angiogenesis
metastasis,
inducing
drug
resistance,
reshaping
extracellular
matrix,
developing
an
immunosuppressive
Owing
to
their
robust
tumor-promoting
function,
are
considered
promising
target
for
oncotherapy.
However,
highly
heterogeneous
group
cells.
Some
subpopulations
exert
inhibitory
role
growth,
which
implies
that
CAF-targeting
approaches
must
be
more
precise
individualized.
This
review
comprehensively
summarize
origin,
phenotypical,
functional
heterogeneity
CAFs.
More
importantly,
we
underscore
advances
strategies
clinical
trials
CAF
various
cancers,
also
progressions
immunotherapy.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Nov. 22, 2023
The
intricacy
of
diseases,
shaped
by
intrinsic
processes
like
immune
system
exhaustion
and
hyperactivation,
highlights
the
potential
renormalization
as
a
promising
strategy
in
disease
treatment.
In
recent
years,
our
primary
focus
has
centered
on
γδ
T
cell-based
immunotherapy,
particularly
pioneering
use
allogeneic
Vδ2
Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: Sept. 18, 2023
Antibody-Drug
Conjugates
(ADCs)
represent
an
innovative
class
of
potent
anti-cancer
compounds
that
are
widely
used
in
the
treatment
hematologic
malignancies
and
solid
tumors.
Unlike
conventional
chemotherapeutic
drug-based
therapies,
mainly
associated
with
modest
specificity
therapeutic
benefit,
three
key
components
form
ADC
(a
monoclonal
antibody
bound
to
a
cytotoxic
drug
via
chemical
linker
moiety)
achieve
remarkable
improvement
terms
targeted
killing
cancer
cells
and,
while
sparing
healthy
tissues,
reduction
systemic
side
effects
caused
by
off-tumor
toxicity.
Based
on
their
beneficial
mechanism
action,
15
ADCs
have
been
approved
date
market
approval
Food
Drug
Administration
(FDA),
European
Medicines
Agency
(EMA)
and/or
other
international
governmental
agencies
for
use
clinical
oncology,
hundreds
undergoing
evaluation
preclinical
phases.
Here,
our
aim
is
provide
comprehensive
overview
features
revolving
around
strategy
including
structural
targeting
properties,
role
tumor
microenvironment
review
providing
discussion
regarding
toxicity
profile,
manifestations
novel
combination
therapies.
Finally,
we
briefly
pathological
contexts
information
manufacturing
analytical
characterization.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(12), P. 3888 - 3888
Published: June 7, 2023
Globally,
clear-cell
renal
cell
carcinoma
(ccRCC)
represents
the
most
prevalent
type
of
kidney
cancer.
Surgery
plays
a
key
role
in
treatment
this
cancer,
although
one
third
patients
are
diagnosed
with
metastatic
ccRCC
and
about
25%
will
develop
recurrence
after
nephrectomy
curative
intent.
Molecular-target-based
agents,
such
as
tyrosine
kinase
inhibitors
(TKIs)
immune
checkpoint
(ICIs),
recommended
for
advanced
cancers.
In
addition
to
cancer
cells,
tumor
microenvironment
(TME)
includes
non-malignant
types
embedded
an
altered
extracellular
matrix
(ECM).
The
evidence
confirms
that
interactions
among
cells
TME
elements
exist
thought
play
crucial
roles
development
making
them
promising
therapeutic
targets.
TME,
unfavorable
pH,
waste
product
accumulation,
competition
nutrients
between
may
be
regarded
further
possible
mechanisms
escape.
To
enhance
immunotherapies
reduce
resistance,
it
is
first
understand
how
work
interact
other
cancer-associated
complex
microenvironment.
